WuXi STA Changzhou site passes first FDA inspection

7 May 2018

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval.

STA Pharmaceutical's API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the US FDA – with no Form 483s issued. This is the first time that WuXi STA’s Changzhou facility has been inspected by the FDA.

WuXi STA Changzhou site passes first FDA inspection
WuXi STA Changzhou site.

WuXi STA has already passed several inspections from the FDA at its API and advanced intermediate manufacturing facility in Shanghai, Jinshan and at its drug product manufacturing facility in Shanghai, Waigaoqiao free trade zone. WuXi STA is the first CMC platform (including both APIs and drug product) in China to have passed FDA inspection for new chemical entities. It is also the first CDMO in China that is approved to supply APIs and GMP intermediates for branded commercial drugs by regulatory agencies in the US, China, EU, Canada, Switzerland, Australia, and New Zealand.

The Changzhou facility – which opened in early 2016 and is situated on a site of 39 acres – has been designed to keep pace with the increasing demand WuXi STA is seeing from customers, as more products move into commercial production.

Currently, the facility employs more than 1000 people including 200 scientists, and has three plants in operation. The company will continue to add more than 300 scientists and seven multi-functional plants within the next 5 years. As a purpose-built facility, Changzhou offers an integrated one-site solution for partners to accelerate innovative APIs and advanced intermediates – from preclinical and clinical development through to global commercial launch.

“Quality is ingrained throughout our culture here at WuXi STA and one of our core competencies. The Changzhou facility passing its first FDA inspection, with no observations – or even written or verbal recommendations – is yet further proof of our commitment to the highest possible quality standards. It’s a point of great pride that we have an exemplary regulatory record, and evidence of the company’s ability to supply the U.S. market with innovative commercial APIs from the Changzhou site.” said Dr Minzhang Chen, CEO of WuXi STA.

“We are very proud of successfully passing FDA inspection once more,” commented Ms Mei Hao, Vice President of Quality at WuXi STA, “we will continue to strengthen our global quality systems to meet and surpass even the most stringent regulatory requirements. This ensures we provide the highest standard of quality services to our partners worldwide.”

Read More

Related news

Compact serialization-ready manual workstation

Compact serialization-ready manual workstation

11 Aug 2018

A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
BASF receives award for its portfolio of natural cosmetic ingredients

BASF receives award for its portfolio of natural cosmetic ingredients

7 Aug 2018

Company recognised for its innovation and continual delivery of new natural ingredients.

Read more 
Extended distribution agreement enables customers to continuously improve their bioprocesses

Extended distribution agreement enables customers to continuously improve their bioprocesses

6 Aug 2018

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

3 Aug 2018

The plant will be first-of-its-kind in the US.

Read more 
Croda invests in SiSaf’s novel bio-courier technology

Croda invests in SiSaf’s novel bio-courier technology

3 Aug 2018

ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Read more 
Breast cancer device receives FDA approval

Breast cancer device receives FDA approval

3 Aug 2018

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Cherwell publishes guide on environmental monitoring processes and validation

Cherwell publishes guide on environmental monitoring processes and validation

31 Jul 2018

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

Read more